<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00553332</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2009-00251</org_study_id>
    <secondary_id>OSU 07056</secondary_id>
    <secondary_id>OSU-07056</secondary_id>
    <secondary_id>CDR0000573452</secondary_id>
    <secondary_id>N01CM62208</secondary_id>
    <secondary_id>N01CM62207</secondary_id>
    <nct_id>NCT00553332</nct_id>
    <nct_alias>NCT01645644</nct_alias>
  </id_info>
  <brief_title>Selumetinib in Treating Patients With Biliary Cancer That Cannot Be Removed By Surgery</brief_title>
  <official_title>A Phase 2 Study of AZD6244 in Biliary Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase II trial is studying how well selumetinib works in treating patients with biliary
      cancer that cannot be removed by surgery. Selumetinib may stop the growth of tumor cells by
      blocking some of the enzymes needed for cell growth.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To evaluate the objective response rate (complete response [CR] and partial response [PR])
      in patients with unresectable biliary carcinoma treated with AZD6244 (selumetinib).

      SECONDARY OBJECTIVES:

      I. To evaluate the toxicity profile of this drug in these patients. II. To evaluate the 6-
      and 12-month survival, 6-month progression-free survival, and overall survival rates of
      patients treated with this drug.

      III. To correlate genetic mutations, epigenetic silencing, and/or protein levels of
      RAS/RAF/MEK/ERK signaling pathway activation with therapeutic efficacy of AZD6244 in these
      patients.

      IV. To genotype tumors for the presence of RAS mutations (i.e., NRAS, KRAS, HRAS) and BRAF
      mutations (e.g., V600E) in biliary tumor samples from these patients.

      V. To assess the presence of activation of the MEK1, MEK2, ERK, and/or Akt pathways in tumor
      samples from these patients.

      VI. To assess the epigenetic alterations (i.e., methylation) affecting the level of
      gene/protein expression of RASSF1A, NORE1A, and NORE1B in tumor samples from these patients.

      OUTLINE:

      Patients receive oral selumetinib twice daily on days 1-28. Courses repeat every 28 days in
      the absence of disease progression or unacceptable toxicity.

      Formalin fixed paraffin-embedded tissue blocks or fresh tissue samples are obtained from all
      patients prior to treatment. Tissue samples are analyzed by immunohistochemistry for the
      expression level of target proteins (MEK, p-MEK, ERK, p-ERK, Akt, p-AKT, RASSF1A, NORE1A and
      NORE1B); PCR for mutational status of target genes RAS, BRAF and EGFR); and in
      methylation-specific PCR for methylation of target gene promoters (promoters for RASSF1A,
      NORE1A and NORE1B). Samples are also analyzed by quantitative real-time PCR to compare
      methylation status. Fresh frozen tissue, when available, is evaluated by Western analysis to
      measure expression levels of target proteins.

      After completion of study treatment, patients are followed up for 4 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (CR and PR)</measure>
    <time_frame>Every 8 weeks</time_frame>
    <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity Profile of AZD6244</measure>
    <time_frame>From the time of first treatment with AZD6244, assessed up to 4 weeks</time_frame>
    <description>Toxicitity will be assessed using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v 3.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Progression Free Survival for Patients</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RAS/RAF/MEK/ERK Signaling Pathway Activation</measure>
    <time_frame>At baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Protein Levels of RAS/RAF/MEK/ERK Signaling Pathway Activation</measure>
    <time_frame>At baseline</time_frame>
    <description>Measure the proteins levels of RAS/RAF/MEK/ERK signaling pathway activation to AZD6244</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Liver and Intrahepatic Biliary Tract Cancer</condition>
  <condition>Recurrent Extrahepatic Bile Duct Cancer</condition>
  <condition>Unresectable Extrahepatic Bile Duct Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment (enzyme inhibitor therapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral selumetinib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>selumetinib</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Treatment (enzyme inhibitor therapy)</arm_group_label>
    <other_name>ARRY-142886</other_name>
    <other_name>AZD6244</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (enzyme inhibitor therapy)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed biliary tract carcinoma

               -  Surgically unresectable disease

          -  Meets any of the following criteria for biliary cancers only:

               -  Received ≤ 1 prior systemic anticancer therapy, including chemoembolization

               -  Received prior cryotherapy, radiofrequency ablation, ethanol injection,
                  transarterial chemoembolization, or photodynamic therapy AND meets the following
                  criteria:

                    -  More than 6 weeks have elapsed since any of the prior therapy described
                       above

                    -  Indicator lesion(s) must be outside the area of prior treatment OR must
                       demonstrate clear evidence of disease progression if the only indicator
                       lesion is inside the prior treatment area

                    -  Indicator lesion must have clearly distinct edges on CT scan

               -  Prior radiotherapy with or without the use of a fluoropyrimidine as a
                  radiosensitizer is allowed, provided more than 12 weeks have elapsed since
                  treatment

          -  Fresh or paraffin-embedded tissue from tumor blocks must be available for review

          -  Measurable disease, defined as ≥ 1 unidimensionally measurable lesion &gt; 20 mm by
             conventional techniques or &gt; 10 mm by spiral CT scan

          -  No known brain metastases

          -  Life expectancy &gt; 12 weeks

          -  ECOG performance status (PS) 0-1 or Karnofsky PS 70-100%

          -  ANC ≥ 1,500/μL

          -  Platelet count ≥ 75,000/μL

          -  Total bilirubin ≤ 2 times upper limit of normal(ULN)

          -  AST or ALT ≤ 3 times ULN

          -  Serum albumin ≥ 2.5 mg/dL

          -  INR ≤ 1.5 (not receiving anticoagulation therapy)

          -  Creatinine normal or creatinine clearance ≥ 60 mL/min

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile women must use effective contraception during and for four weeks after the
             last dose of AZD6244

          -  Fertile men must use effective contraception during and for 16 weeks after the last
             dose of AZD6244

          -  No significant traumatic injury within the past 3 weeks

          -  No uncontrolled symptoms consistent with encephalopathy

          -  No history of allergic reactions attributed to compounds of similar chemical or
             biologic composition to AZD6244 or its excipient, Captisol®

          -  No QTc interval &gt; 500 msecs or other factors that increase the risk of QT prolongation
             or arrhythmic events (e.g., hypokalemia or family history of long QT interval
             syndrome), including NYHA class III-IV heart failure

          -  No other malignancy within the past 3 years, except adequately treated basal cell or
             squamous cell skin cancer or carcinoma in situ of the cervix

          -  No refractory nausea and vomiting, chronic gastrointestinal disease (e.g.,
             inflammatory bowel disease), or significant bowel resection that would preclude
             adequate absorption

          -  No uncontrolled concurrent illness including, but not limited to, ongoing or active
             infection or psychiatric illness/social situation that would limit compliance with
             study requirements

          -  No malignant hypertension within the past year

          -  No prior sorafenib or MEK inhibitors

          -  More than 4 weeks since prior chemotherapy, biologic therapy, or immunotherapy (6
             weeks for nitrosoureas or mitomycin C) and recovered to ≤ grade 1 adverse events

          -  No major surgery within the past 3 weeks

          -  No other concurrent investigational agents

          -  No concurrent requirement for medication that can prolong the QT interval

          -  No concurrent combination antiretroviral therapy for HIV-positive patients

          -  No concurrent consumption of grapefruit or grapefruit juice
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tanios Bekaii-Saab</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Cancer Center (UMCC) Research Base</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-0352</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne State University</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Bekaii-Saab T, Phelps MA, Li X, Saji M, Goff L, Kauh JS, O'Neil BH, Balsom S, Balint C, Liersemann R, Vasko VV, Bloomston M, Marsh W, Doyle LA, Ellison G, Grever M, Ringel MD, Villalona-Calero MA. Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers. J Clin Oncol. 2011 Jun 10;29(17):2357-63. doi: 10.1200/JCO.2010.33.9473. Epub 2011 Apr 25.</citation>
    <PMID>21519026</PMID>
  </results_reference>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 2007</study_first_submitted>
  <study_first_submitted_qc>November 2, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 5, 2007</study_first_posted>
  <results_first_submitted>September 11, 2015</results_first_submitted>
  <results_first_submitted_qc>March 22, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 22, 2016</results_first_posted>
  <last_update_submitted>March 22, 2016</last_update_submitted>
  <last_update_submitted_qc>March 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bile Duct Neoplasms</mesh_term>
    <mesh_term>Cholangiocarcinoma</mesh_term>
    <mesh_term>Biliary Tract Neoplasms</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were enrolled to the trial between December 2007 and January 2009</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment (Enzyme Inhibitor Therapy)</title>
          <description>Patients receive oral selumetinib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
selumetinib: Given orally
laboratory biomarker analysis: Correlative studies</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28">evaluable for response</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>ineligible, incorrect diagnosis</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All patients had metastatic disease.</population>
      <group_list>
        <group group_id="B1">
          <title>Treatment (Enzyme Inhibitor Therapy)</title>
          <description>Patients receive oral selumetinib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
selumetinib: Given orally
laboratory biomarker analysis: Correlative studies</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="28"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.6" lower_limit="26" upper_limit="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>patients</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>patients</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>patients</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Eastern Cooperative Oncology Group (ECOG)</title>
          <units>patients</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>0 (Fully active)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 (Restricted activity)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Disease site</title>
          <units>patients</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Intrahepatic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gallbladder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extrahepatic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Metastasis site</title>
          <units>patients</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Liver only</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Liver and other sites</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other (soft tissue, lymph nodes and lung)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of target lesions</title>
          <units>lesions</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4" lower_limit="1" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Objective Response Rate (CR and PR)</title>
        <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR</description>
        <time_frame>Every 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Enzyme Inhibitor Therapy)</title>
            <description>Patients receive oral selumetinib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
selumetinib: Given orally
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate (CR and PR)</title>
          <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR</description>
          <units>patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Toxicity Profile of AZD6244</title>
        <description>Toxicitity will be assessed using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v 3.0</description>
        <time_frame>From the time of first treatment with AZD6244, assessed up to 4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Enzyme Inhibitor Therapy)</title>
            <description>Patients receive oral selumetinib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
selumetinib: Given orally
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Toxicity Profile of AZD6244</title>
          <description>Toxicitity will be assessed using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v 3.0</description>
          <units>percent of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Rash</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Xerostomia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Progression Free Survival for Patients</title>
        <description>Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions</description>
        <time_frame>Up to 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Enzyme Inhibitor Therapy)</title>
            <description>Patients receive oral selumetinib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
selumetinib: Given orally
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Median Progression Free Survival for Patients</title>
          <description>Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" lower_limit="3.5" upper_limit="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <time_frame>Up to 12 months</time_frame>
        <population>Kaplan-Meier</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Enzyme Inhibitor Therapy)</title>
            <description>Patients receive oral selumetinib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
selumetinib: Given orally
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <population>Kaplan-Meier</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.8" lower_limit="3.50">Too early to reach the upper 95% confidence interval</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>RAS/RAF/MEK/ERK Signaling Pathway Activation</title>
        <time_frame>At baseline</time_frame>
        <population>Data was not collected and analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Enzyme Inhibitor Therapy)</title>
            <description>Patients receive oral selumetinib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
selumetinib: Given orally
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>RAS/RAF/MEK/ERK Signaling Pathway Activation</title>
          <population>Data was not collected and analyzed</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Protein Levels of RAS/RAF/MEK/ERK Signaling Pathway Activation</title>
        <description>Measure the proteins levels of RAS/RAF/MEK/ERK signaling pathway activation to AZD6244</description>
        <time_frame>At baseline</time_frame>
        <population>Only 27 patients had pAKT and pERK performed due to 2 samples not available for analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Enzyme Inhibitor Therapy)</title>
            <description>Patients receive oral selumetinib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
selumetinib: Given orally
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Protein Levels of RAS/RAF/MEK/ERK Signaling Pathway Activation</title>
          <description>Measure the proteins levels of RAS/RAF/MEK/ERK signaling pathway activation to AZD6244</description>
          <population>Only 27 patients had pAKT and pERK performed due to 2 samples not available for analysis</population>
          <units>mg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>pAKT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.23" spread="0.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pERK</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.36" spread="1.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All patients were evaluated for toxicity using the NCI Common Toxicity Criteria version 3.0 from the time of their first treatment until the end of treatment.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment (Enzyme Inhibitor Therapy)</title>
          <description>Patients receive oral selumetinib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
selumetinib: Given orally
laboratory biomarker analysis: Correlative studies</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE version 3.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Xerostomia</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Bloating</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="25" subjects_affected="25" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Dry Skin</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Tanios Bekaii-Saab, MD</name_or_title>
      <organization>The Ohio State University Comprehensive Cancer Center-James Cancer Hospital and Solove Research Institute</organization>
      <phone>614-293-9863</phone>
      <email>Tanios.Bekaii-Saab@osumc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

